Serum JKAP as a potential prognostic biomarker in acute coronary syndrome patients undergoing percutaneous coronary intervention.

ABSTRACT:

Objective

Our previous studies revealed that knockdown of JNK pathway-associated phosphatase (JKAP) facilitates atherosclerotic progression by regulating CD4⁺ T-cell differentiation. Moreover, CD4⁺ T-cell subtypes are dysregulated and can serve as a prognosis biomarker in acute coronary syndrome (ACS) patients who have undergone percutaneous coronary intervention (PCI). This study aims to further investigate the correlation between JKAP with CD4⁺ T-cell subtypes and prognosis in ACS patients who have undergone PCI.

Methods

This study included 173 ACS patients, for whom serum JKAP levels were detected before PCI and 1 month (M1) after PCI via an enzyme-linked immunosorbent assay. Short physical performance battery (SPPB) scores at M1 and major

SUBMITTER: Chen X 

PROVIDER: S-EPMC12741847 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature